[Calcium-sensing receptor and hypoparathyroidism].
Serum level of parathyroid hormone (PTH) is strictly regulated by serum calcium concentration, which is sensed by the calcium-sensing receptor (CaSR) , a member of G-protein-coupled-receptor superfamily. Activating CaSR mutations result in the impaired PTH secretion and hypocalcemia, and the increased sensitivity of the receptor in kidney leads to relative hypercalciuria despite hypocalcemia. Recognizing the patients with activating mutations in CaSR is quite important, because these patients can exhibit unusual sensitivity to treatment of their hypocalcemia with calcium and vitamin D supplementation, with toxic effects including nephrocalcinosis, renal stones, and diminished renal function.
Osaka Medical Center and Research Institute for Maternal and Child Health, Department of Bone and Mineral Research, Japan.
Toshimi
T
Michigami
D002118:Calcium / Q000097:blood / Q000502:physiology; D003937:Diagnosis, Differential; D006801:Humans; D053565:Hypercalciuria / Q000209:etiology; D006996:Hypocalcemia / Q000209:etiology; D007011:Hypoparathyroidism / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics* / Q000503:physiopathology; D009154:Mutation; D010281:Parathyroid Hormone / Q000378:metabolism; D044169:Receptors, Calcium-Sensing / Q000235:genetics* / Q000502:physiology
D010281:Parathyroid Hormone; D044169:Receptors, Calcium-Sensing; D002118:Calcium